You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline characteristics of the study population by origin, n = 726

From: Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study

Baseline Characteristics Norwegian-born Foreign-born Total p-value
Number of individuals 131 (100) 595 (100) 726 (100)  
Gender     0.115
 Male 69 (53) 358 (60) 427 (59)  
Age at notification     > 0.001
 < 5 years 37 (28) 25 (4) 62 (9)  
 5–14 years 10 (8) 132 (22) 142 (20)  
 15–34 years 33 (25) 315 (53) 348 (48)  
 35–64 years 36 (27) 115 (19) 151 (21)  
> 65 years 15 (11) 8 (1) 23 (3)  
Risk groupsa
Any risk factora 121(92) 342 (58) 463 (64)  
Recent exposure, contacts 68 (52) 95 (16) 163 (22) > 0.001
 Contacts < 5 years 35 (27) 3 (0.5) 38 (5)  
Positive chest X-ray, any 7 (5) 60 (10) 67 (9) 0.090
 Fibrotic lesions 2 (2) 17 (3) 19 (3) 0.388
Immunosuppressive condition 51 (39) 72 (12) 123 (17) > 0.001
 HIV infection 12 (2) 12 (2)  
 Chronic renal disease 1 (1) 4 (1) 5 (1)  
 Diabetes, any 1 (1) 4 (1) 5 (1)  
 Underlying disease relevant for Immunosuppressive treatmentb 13 (10) 10 (2) 23 (3)  
 Other medical conditionsc 36 (7) 42 (7) 78 (15)  
Interferon Gamma Release Assay (IGRA)     > 0.001
 Positive 94 (72) 577 (97) 671 (92)  
 Negative 15 (11) 5 (1) 20 (3)  
 Inconclusive 2 (2) 2 (0)  
 Missing or unknown 20 (15) 13 (2) 33 (5)  
Regimen     > 0.001
 3RH dailyI 97 (74) 302 (51) 399 (55)  
 3RPH weeklyII 30 (23) 276 (46) 306 (42)  
 4R or 6H monotherapy dailyIII 3 (2) 15 (3) 18 (2)  
 OtherIV 2 (0) 2 (0)  
 Missing 1 (1) 1 (0)  
TB IR (per 100,000) in country of birth#
 < 150 na 267 (45) 267 (45)  
 150–200 na 127 (21) 127 (21)  
 > 200 na 197 (33) 197 (33)  
 Missing na 4 (1) 4 (1)  
  1. Data are presented as n (%) or median [interquartile range]. % refers to columns and not rows
  2. aAccording to Norwegian guidelines for the management and control of tuberculosis: with strong or conditional recommendation for LTBI treatment (age < 15 years, known exposure, positive chest X-ray or immunosuppressive condition)
  3. bIncludes rheumatologic-, dermatologic-, neurologic- and gastroenterological medical conditions
  4. cOther medical conditions include unspecified immunosuppressive conditions reported by the clinician
  5. I3RH: rifampicin (R) and isoniazid (H) daily for three months
  6. II3RPH: rifapentine (RP) and isoniazid (H) in 12 weekly doses
  7. IIIRifampicin (R) monotherapy daily for four months or isoniazid (H) monotherapy daily for six months
  8. IVOthers include full-course TB treatments for two individuals for two and four months respectively
  9. # Four immigrants had missing information on country of birth